Published in AIDS Weekly, September 22nd, 1997
The U.S. Food and Drug Administration (FDA) advisory committee heard two days of testimony about the safety and efficacy of Celgene Corp's version of the drug, known as Synovir, in treating a painful side-effect of leprosy known as erythema nodosum leprosum (ENL).
In an unusual move, the panel advised licensing of all versions of the drug, not just Celgene's formulation. But, mindful of testimony from patients of thalidomide, they recommended severely restricting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.